Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 6/2015

01.06.2015 | Review

Very late recurrence (after more than 20 years) of epithelial ovarian carcinoma: case report and literature review

verfasst von: Joseph Menczer, Letizia Schreiber, Ofri Peled, Tally Levy

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To present a case of very late (more than 20 years) recurrence of epithelial ovarian carcinoma and to review the pertinent literature. We encountered a 50-year-old patient who, at the age of 22, underwent cytoreductive surgery and adjuvant chemotherapy for stage III serous ovarian carcinoma. She recurred after 28 years and underwent secondary surgery and chemotherapy.

Method

A PubMed search of the English literature containing the following key words: ovarian cancer, late recurrence, late relapse, late metastasis was performed.

Results

Only five cases (including the present one) with recurrence after more than 20 years are so far on record. Of these, four patients were 33 years old or younger and had advanced stage at diagnosis. Time to recurrence ranged from 21 to 28 years. All patients had serous carcinoma and three had recurrence in lymph nodes.

Conclusions

Very late recurrence is an extremely rare event and may result from either regrowth of dormant tumor cells or from development of a new cancer. Lifelong follow-up is critically important for ovarian cancer patients.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. 55:74 Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. 55:74
2.
Zurück zum Zitat Ozols RF (2006) Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33(2 Suppl 6):S3–S11CrossRefPubMed Ozols RF (2006) Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33(2 Suppl 6):S3–S11CrossRefPubMed
3.
Zurück zum Zitat Dowdy SC, Pfeifer EA, Longcope DC, Cliby WA (1999) Unusual recurrence of ovarian carcinoma 9 years after initial diagnosis. Gynecol Oncol 74:495–498CrossRefPubMed Dowdy SC, Pfeifer EA, Longcope DC, Cliby WA (1999) Unusual recurrence of ovarian carcinoma 9 years after initial diagnosis. Gynecol Oncol 74:495–498CrossRefPubMed
4.
Zurück zum Zitat Bamias A, Efstathiou E, Vassilakopoulou M, Koutsoukou V, Papadimitriu C, Rodolakis A et al (2005) Late relapse of epithelial ovarian cancer: a single institution experience. Eur J Gynaecol Oncol 26:439–442PubMed Bamias A, Efstathiou E, Vassilakopoulou M, Koutsoukou V, Papadimitriu C, Rodolakis A et al (2005) Late relapse of epithelial ovarian cancer: a single institution experience. Eur J Gynaecol Oncol 26:439–442PubMed
5.
Zurück zum Zitat Sahdev A, Hughes JH, Barwick T, Rockall AG, Gallagher CJ, Reznek RH (2007) Computed tomography features of recurrent ovarian carcinoma according to time to relapse. Acta Radiol 48:1038–1044CrossRefPubMed Sahdev A, Hughes JH, Barwick T, Rockall AG, Gallagher CJ, Reznek RH (2007) Computed tomography features of recurrent ovarian carcinoma according to time to relapse. Acta Radiol 48:1038–1044CrossRefPubMed
6.
Zurück zum Zitat Testelmans D, Van Raemdonck D, Amant F, De Wever W, Verbeken E, Nackaerts K (2010) Late recurrent ovarian carcinoma metastatic to the thoracic wall. Acta Clin Belg 65:354–356CrossRefPubMed Testelmans D, Van Raemdonck D, Amant F, De Wever W, Verbeken E, Nackaerts K (2010) Late recurrent ovarian carcinoma metastatic to the thoracic wall. Acta Clin Belg 65:354–356CrossRefPubMed
7.
Zurück zum Zitat Zylberberg B, Dormont D, Madelenat P, Daraï E (2004) Relapse after more than 20 years of follow-up for epithelial ovarian carcinoma. Obstet Gynecol 103:1082–1084CrossRefPubMed Zylberberg B, Dormont D, Madelenat P, Daraï E (2004) Relapse after more than 20 years of follow-up for epithelial ovarian carcinoma. Obstet Gynecol 103:1082–1084CrossRefPubMed
8.
Zurück zum Zitat Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ (1998) Field cancerization: why late “recurrent” ovarian cancer is not recurrent. Am J Obstet Gynecol 178:641–649CrossRefPubMed Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ (1998) Field cancerization: why late “recurrent” ovarian cancer is not recurrent. Am J Obstet Gynecol 178:641–649CrossRefPubMed
9.
Zurück zum Zitat Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BAJ et al (1992) Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84:1793–1798CrossRefPubMed Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BAJ et al (1992) Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84:1793–1798CrossRefPubMed
10.
Zurück zum Zitat Ruppender NS, Morrissey C, Lange PH, Vessella RL (2013) Dormency in solid Tumors implication for prostate cancer. Cancer Metastasis Rev 32:501–509CrossRefPubMed Ruppender NS, Morrissey C, Lange PH, Vessella RL (2013) Dormency in solid Tumors implication for prostate cancer. Cancer Metastasis Rev 32:501–509CrossRefPubMed
11.
12.
Zurück zum Zitat Winquist RJ, Boucher DM, Wood M, Furey BF (2009) Targeting cancer stem cells for more effective therapies: taking out cancer’s locomotive engine. Biochem Pharmacol 78:326–334CrossRefPubMed Winquist RJ, Boucher DM, Wood M, Furey BF (2009) Targeting cancer stem cells for more effective therapies: taking out cancer’s locomotive engine. Biochem Pharmacol 78:326–334CrossRefPubMed
13.
Zurück zum Zitat Tomao F, Papa A, Strudel M, Rossi L, Lo Russo G, Benedetti Panici P et al (2014) Investigating molecular profiles of ovarian cancer: an update on cancer stem cells. J Cancer 5:301–310CrossRefPubMedCentralPubMed Tomao F, Papa A, Strudel M, Rossi L, Lo Russo G, Benedetti Panici P et al (2014) Investigating molecular profiles of ovarian cancer: an update on cancer stem cells. J Cancer 5:301–310CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Murphy SK (2010) Targeting ovarian cancer-initiating cells. Anticancer Agents Med Chem 10:157–163CrossRefPubMed Murphy SK (2010) Targeting ovarian cancer-initiating cells. Anticancer Agents Med Chem 10:157–163CrossRefPubMed
15.
Zurück zum Zitat Zhou B-BS, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009) Tumour initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806–823CrossRefPubMed Zhou B-BS, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009) Tumour initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806–823CrossRefPubMed
16.
Zurück zum Zitat Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al (2008) Identification and characterization of ovarian cancer Initiating cells from primary human tumors. Cancer Res 68:4311–4320CrossRefPubMedCentralPubMed Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al (2008) Identification and characterization of ovarian cancer Initiating cells from primary human tumors. Cancer Res 68:4311–4320CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Vang R, Shih IeM, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16:267–282CrossRefPubMedCentralPubMed Vang R, Shih IeM, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16:267–282CrossRefPubMedCentralPubMed
Metadaten
Titel
Very late recurrence (after more than 20 years) of epithelial ovarian carcinoma: case report and literature review
verfasst von
Joseph Menczer
Letizia Schreiber
Ofri Peled
Tally Levy
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 6/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-014-3597-6

Weitere Artikel der Ausgabe 6/2015

Archives of Gynecology and Obstetrics 6/2015 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.